ReviewCancer medicine2019
A good start of immunotherapy in esophageal cancer.
Review in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.BMC cancer · 2023Pooled it
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- Neoadjuvant immunochemotherapy for resectable esophageal cancer: A study on efficacy and safety.Biomolecules & biomedicine · 2025Article
- Enhancing survival in locally advanced esophageal cancer: a comparative analysis of neoadjuvant immunotherapy versus conventional neoadjuvant therapies using the SEER database.Journal of thoracic disease · 2025Article
- Identification of immune subtypes associated with CD8+ T cell-related genes providing new treatment strategies of esophageal carcinoma.Frontiers in immunology · 2025Article
- An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers.Frontiers in immunology · 2025Article
- CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges.Advanced biomedical research · 2025Review
- Review
- A computed tomography-based nomogram for neoadjuvant chemotherapy plus immunotherapy response prediction in patients with advanced esophageal squamous cell carcinoma.Frontiers in oncology · 2024Article
- CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.Frontiers in immunology · 2024Article
- Prediction of Survival in Patients With Esophageal Cancer After Immunotherapy Based on Small-Size Follow-Up Data.IEEE open journal of engineering in medicine and biology · 2024Article
- Neoadjuvant therapy for non-small cell lung cancer and esophageal cancer.American journal of cancer research · 2024Review
- A predictive scoring model to select suitable patients for surgery on primary tumor in metastatic esophageal cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- Contrast-enhanced CT-based radiomic analysis for determining the response to anti-programmed death-1 therapy in esophageal squamous cell carcinoma patients: A pilot study.Thoracic cancer · 2023Article
- Intracellular Fusobacterium nucleatum infection attenuates antitumor immunity in esophageal squamous cell carcinoma.Nature communications · 2023Article
- The pharmacological mechanism of β-elemene in the treatment of esophageal cancer revealed by network pharmacology and experimental verification.Scientific reports · 2023Article
- Construction of a novel pyrotosis-related prognostic model of esophageal square cell carcinoma and determination of the anti-tumor effect of WFDC12.Functional & integrative genomics · 2023Article
- Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3/GSDME-mediated pyroptosis.Cell death discovery · 2023Article
- Characterization of the Immune Infiltration Landscape and Identification of Prognostic Biomarkers for Esophageal Cancer.Molecular biotechnology · 2023Article
- Artificial Intelligence-Assisted Transcriptomic Analysis to Advance Cancer Immunotherapy.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the benefits of immunotherapy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the application of immunotherapy such as immune checkpoint inhibitors, peptide vaccine, adoptive T cell transfer and oncolytic virus in esophageal cancer. Some already have preliminary results and show the advantages of immunotherapy in esophageal cancer, while others are still in progress. This review aims to introduce the feasibility and current status of immunotherapy in esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.